-
Board Certification
American Board of Obstetrics & GynecologyAmerican Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)Patient Rating
4.9 /5( out of 88 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 29, 2024HUNTSMAN CANCER CENTERDr. Maurer provides excellent medical care!
October 29, 2024HUNTSMAN CANCER CENTERDr. Maurer is amazing! Exceptional skills coupled with compassionate honesty make her a trusted surgeon.
October 22, 2024HUNTSMAN CANCER CENTEROutstanding physician in every regard. She addressed all concerns and did so thoroughly and in a way that was easily understandable. She did not make Md feel rushed. She heard my concerns - both those spoken and those not spoken. Instinctive. Smart. Well read. Up-to-date on all published peer reviewed medical & scientific literature. So much better than I could have even anticipated. I feel assured that my care will be the best it can be. In a word (or two): World class.
October 22, 2024HUNTSMAN CANCER CENTERWOW She is AWESOME. Smart, compassionate and answers all my questions so i can understand. One of the best doctors I have ever been to. I was so scare for surgery but she is so skilled and compassionate and kind.
October 17, 2024HUNTSMAN CANCER CENTERKathryn Mauer is one of the best doctors anyone could be lucky to have! She is brilliant and saved my life!
October 16, 2024HUNTSMAN CANCER CENTERI would highly recommend Dr Maurer.
September 24, 2024HUNTSMAN CANCER CENTERShe cares about you as a person. She spends time. She explains and listens.
September 24, 2024HUNTSMAN CANCER CENTERDr. Maurer is very knowledgeable, very kind, and attentive. Her personality is contagious. I truly loved her as my surgeon.
September 11, 2024HUNTSMAN CANCER CENTERWould recommend Dr Maurer and her Team to anyone. Very caring and willing to explain and answer all questions
-
Board Certification and Academic Information
Academic Departments Obstetrics & Gynecology -Primary Academic Divisions Gynecological Oncology
Board Certification American Board of Obstetrics & GynecologyAmerican Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)Education history
Fellowship Gynecologic Oncology - Cleveland Clinic Fellow Obstetrics and Gynecology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident Professional Medical Medicine - ÈËÆÞÖгöÊÓƵ of Michigan Medical School M.D. Geology, Biology - Brown ÈËÆÞÖгöÊÓƵ Sc.B. Selected Publications
Journal Article
- Barnard ME, Farland LV, Yan B, Wang J, Trabert B, Doherty JA, Meeks HD, Madsen M, Guinto E, Collin LJ, Maurer KA, Page JM, Kiser AC, Varner MW, Allen-Brady K, Pollack AZ, Peterson KR, Peterson CM, Schliep KC (2025). Endometriosis Typology and Ovarian Cancer Risk. JAMA, 332(6), 482-489. ()
- Scaglione MA, Allshouse AA, Canfield DR, Mclaughlin HD, Bruno AM, Hammad IA, Branch DW, Maurer KA, Dood RL, Debbink MP, Silver RM, Einerson BD (2022). Prophylactic Ureteral Stent Placement and Urinary Injury During Hysterectomy for Placenta Accreta Spectrum. Obstet Gynecol, 140(5), 806-811. ()
- Straubhar AM, Parsons MW, Francis S, Gaffney D, Maurer KA (2021). Refusal of surgery and survival outcomes in endometrial cancer. Int J Gynecol Cancer, 31(9), 1236-1241. ()
- Casper AC, Parsons MW, Chipman J, Burt LM Jr, Suneja G, Maurer KA, Gaffney DK (2021). Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol, 162(2), 454-460. ()
- Parsons MW, Francis S, Maurer KA, Grant J, Gaffney DK (2020). Refusal of Radiation Results in Inferior Survival in Endometrial Cancer. Am J Clin Oncol, 43(6), 399-410. ()
- Harris KL, Maurer KA, Jarboe E, Werner TL, Gaffney D (2019). LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT? Gynecol Oncol, 156(1), 243-250. ()
- McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, Werner TL, Gaffney DK (2019). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol, 156(1), 85-92. ()
- Rodriguez AC, Blanchard Z, Maurer KA, Gertz J (2019). Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. Horm Cancer, 10(2-3), 51-63. ()
- Gaffney DK, Hashibe M, Kepka D, Maurer KA, Werner TL (2018). Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol, 151(3), 547-554. ()
- Maurer K, Michener C, Mahdi H, Rose PG (2016). Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. J Gynecol Oncol, 28(4), e38. ()
Case Report
- Wei M, Maurer KA, Henry NL (2019). Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy. Breast J, 25(6), 1254-1256. ()